Price
CHART BY
Frequently asked questions
What is Veracyte's market capitalization?
The market capitalization of Veracyte is $3.04B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Veracyte?
Veracyte's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.145. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Veracyte's stock?
Currently, 12 analysts cover Veracyte's stock, with a consensus target price of $46.20. Analyst ratings provide insights into the stock's expected performance.
What is Veracyte's revenue over the trailing twelve months?
Over the trailing twelve months, Veracyte reported a revenue of $425.33M.
What is the EBITDA for Veracyte?
Veracyte's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $34.80M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Veracyte?
Veracyte has a free cash flow of $56.48M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Veracyte have, and what sector and industry does it belong to?
Veracyte employs approximately 815 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Veracyte's shares?
The free float of Veracyte is 76.57M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $3.04B
- EPS (TTM)
- -$0.145
- Free Float
- 76.57M
- Revenue (TTM)
- $425.33M
- EBITDA (TTM)
- $34.80M
- Free Cashflow (TTM)
- $56.48M
Pricing
- 1D span
- $38.40$41.93
- 52W span
- $18.61$47.17
Analyst Ratings
The price target is $46.20 and the stock is covered by 12 analysts.
Buy
9
Hold
2
Sell
1
Information
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
- Employees
- 815
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- ISIN
- US92337F1075
- Primary Ticker
- VCYT
Knockouts
Finance data from FactSet